Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis

Affiliation auteurs!!!! Error affiliation !!!!
TitreMulticenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis
Type de publicationJournal Article
Year of Publication2018
AuteursTarfi S, Harrivel V, Dumezy F, Guy J, Roussel M, Mimoun A, Fenaux P, Chapuis N, Solary E, Selimoglu-Buet D, Wagner-Ballon O, GFM
JournalBLOOD CANCER JOURNAL
Volume8
Pagination114
Date PublishedNOV 14
Type of ArticleArticle
ISSN2044-5385
Résumé

Peripheral blood monocytes include three subsets defined by CD14 and CD16 surface markers. An increase in the CD14(++)CD16(-) classical monocyte fraction >= 94% of the total monocytes was proposed to rapidly and efficiently distinguish chronic myelomonocytic leukemia from reactive monocytosis. The robustness of this assay required a multicenter validation. The flow cytometry assay designed to quantify peripheral blood monocyte subsets was implemented by multiple diagnosis laboratories in France. A nationwide survey was performed to evaluate its performance. All the 48 French laboratories answered the questionnaire, revealing that 63% use this assay routinely. Central blind reanalysis of 329 cytometry files collected from five laboratories demonstrated an excellent correlation in classical monocyte fraction measurement (r = 0.93; p < 0.0001). The cutoff value of 94% classical monocytes being the critical readout for diagnosis, we then compared 115 patients with classical monocytes = 94% and 214 patients with a fraction < 94% between initial analysis and reanalysis. An agreement was obtained in 311 files. Finally, an overt diagnosis, available for 86 files, confirmed a good sensitivity (93.6%) and specificity (89.7%). This survey demonstrates the robustness of the flow assay with limited variability of classical monocyte percentage between centers, validates the 94% cutoff value, and confirms its sensitivity and specificity.

DOI10.1038/s41408-018-0146-8